Voyager therapeutics, inc. (VYGR)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Collaboration revenue

117,261

104,391

73,725

55,386

11,874

7,619

11,957

11,011

9,613

10,135

6,151

8,311

10,854

14,220

16,795

18,424

19,588

17,334

0

0

0

Operating expenses:
Research and development

127,198

119,735

100,097

86,952

74,883

64,905

61,319

64,248

63,041

62,260

61,657

52,405

47,589

42,249

38,745

34,917

30,888

27,679

0

0

0

General and administrative

36,882

36,335

34,700

32,846

36,286

33,809

30,919

29,252

22,006

19,738

17,853

16,281

14,619

13,270

12,946

12,051

11,593

9,909

0

0

0

Total operating expenses

164,080

156,070

134,797

119,798

111,169

98,714

92,238

93,500

85,047

81,998

79,510

68,686

62,208

55,519

51,691

46,968

42,481

37,588

0

0

0

Operating loss

-46,819

-51,679

-61,072

-64,412

-99,295

-91,095

-80,281

-82,489

-75,434

-71,863

-73,359

-60,375

-51,354

-41,299

-34,896

-28,544

-22,893

-20,254

0

0

0

Other income:
Interest income

6,290

6,457

5,975

5,094

3,867

3,310

2,828

2,177

1,562

1,227

-294

586

764

976

2,171

1,073

0

-

0

0

-

Other (expense) income

-161

1,625

1,542

480

-104

-683

-280

-478

-58

-62

433

616

763

182

0

0

0

-

-

-

-

Total other income

6,129

8,082

7,517

5,574

3,763

2,627

2,548

1,699

1,504

1,165

139

1,202

1,527

1,158

1,736

0

0

-

0

-

-

Loss before income taxes

-

-

-53,555

-58,838

-

-88,468

-77,733

-80,790

-73,930

-70,698

-73,220

-59,173

-49,827

-40,141

-29,739

0

0

-

0

-

-

Income tax benefit

-

-

-

-

-

-180

0

0

0

-

-334

0

0

-

0

-

-

-

-

-

-

Other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss

-40,690

-43,597

-53,555

-58,838

-95,532

-88,288

-77,584

-80,641

-73,976

-70,698

-73,544

-59,194

-49,653

-40,193

-32,802

-27,723

-22,283

-29,672

0

0

0

Other comprehensive income
Net unrealized gain on available-for-sale-securities

496

29

159

226

87

34

161

-275

-607

-235

-1,085

-30

295

199

939

349

0

-

0

0

-

Cumulative effect adjustment resulting from ASU No. 2016-01

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive income

496

29

39

106

-33

34

281

-155

-487

-235

-1,085

-30

295

199

939

349

0

-

0

0

-

Comprehensive loss

-40,194

-43,568

-53,516

-58,732

-95,565

-88,254

-77,303

-80,796

-74,463

-70,933

-74,629

-59,224

-49,358

-39,994

-32,210

-27,643

-22,253

-29,923

0

0

0

Net income (loss) per share, basic

-

-

-

0.30

-

-

-

-0.80

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

0.29

-

-

-

-0.80

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding, basic

-

-

-

36,610

-

-

-

31,976

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding, diluted

-

-

-

37,941

-

-

-

31,976

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of net loss to net loss attributable to common stockholders:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,373

0

0

0

Accrued dividends on series A preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,245

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29,665

-38,290

0

0

0

Net loss per share, basic and diluted

-0.66

-

-0.41

-

-0.81

-

-0.63

-

-0.63

-0.37

-0.89

-0.73

-0.65

-0.58

-0.35

-0.37

-0.29

36.12

-5.25

-5.94

-15.79

Weighted-average common shares outstanding, basic and diluted

36,963

-

36,742

-

33,353

-

32,191

-

31,759

29,312

26,164

25,946

25,791

25,530

25,374

25,228

25,076

13,311

1,317

1,135

1,001

ASU 2016-01
Cumulative effect adjustment resulting from ASU No. 2016-01

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-